FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M

First Page		Document Content
Date: 2016-04-19 06:39:33 Clinical medicine Medicine Lung cancer Biology KRAS Non-small-cell lung carcinoma Biomarker Ras subfamily FASN Fatty acid synthase		FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M Add to Reading List Source URL: www.3vbio.com Download Document from Source Website File Size: 997,69 KB Share Document on Facebook

	FASN inhibition studies in preclinical tumor models identify biomarkers that align with in vitro and in vivo sensitivity to TVB-2640 Timothy S. Heuer, Richard Ventura, Kasia Mordec, Julie Lai, Joanna Waszczuk, Glenn Hamm DocID: 1sjTl - View Document
	Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 Timothy S. Heuer, Richard Ventura, Julie Lai, Joanna Waszczuk, Kasia Mord DocID: 1rUWL - View Document
	A First-In-Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity A.  Brenner1, J. Infante2, M. Patel3, H DocID: 1rUTE - View Document
	FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M DocID: 1q2yH - View Document
	Preliminary Activity in the First in Human Study of the First-InClass Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 M. Patel1, A. Brenner2, J. Infante3, HT. Arkenau4, E. Borazanci5, G. Falchook6, J. Lopez7, S. Pant8, E. DocID: 1q1rP - View Document